Skip to main content

Table 1 Distribution of baseline variables by concurrent ADT status

From: The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation

Variable ADT No ADT Total p-value no ADT p-value
  (cases) (unmatched controls)   (unmatched) (matched controls) (matched)
  n = 421 n = 797 n = 1218   n = 421  
Mean age 68.63 68.5   0.75 68.4 0.67
Mean PSA 8.47 8.18   0.28 8.12 0.252
Gleason Score (mean) 6.9 6.38   <0.001 6.83 0.99
Race     <0.001   0.042
White 278 (11.7%) 650 (81.6) 928   313 (74.3%)  
Black 79 (18.8%) 96 (12%) 175   67 (15.9%)  
Hispanic 44 (10.4%) 34 (4.3%) 78   27 (6.4%)  
Other 20 (4.8%) 17 (2.1%) 37   14 (3.3%)  
Year of diagnosis (mean) 2003 1997   <0.001 2001 <0.001
Dose of radiation     <0.001   
Low ≤ 70 28 (6.6%) 390 (49.8%) 418   71 (16.9%) <0.001
High > 70 393 (93.3%) 407 (51.1%) 800   350 (8.3%)  
Clinical T-stage     0.27   0.47
T1 205 (48.7%) 336 (42.2%) 571   234 (55.6%)  
T2a 94 (22.3%) 164 (20.1%) 258   95 (22.6%)  
T2b,c 122 (30%) 267 (33.5%) 389   92 (21.8%)  
Length of concurrent hormones*       
Short (≤6 months) 271 (64.4%)   271    
Long (>6 months) 150 (35.6%)   150    
Timing of hormones       
Neoadjuvant 371 (88.1%)   371    
Adjuvant 50 (11.9%)   50    
Salvage 8 (1.9%) 114 (14.3%) 122 <0.001 40 (9.5%) <0.001
Radiation type<       <0.001
3-D conformal 73 (17.3%) 546 (68.5%) 619 <0.001 171 (40.6%)  
IMRT 348 (82.7%) 251 (31.5%) 599   250 (59.4%)  
  1. *(of patients who received adjuvant hormones).
  2. Percentages may not sum to 100% due to rounding.